Clinical trials in neurological disorders using AAV vectors: promises and challenges.
about
Biology of adeno-associated viral vectors in the central nervous systemGene-based therapy of Parkinson's Disease: Translation from animal model to human clinical trial employing convection enhanced deliveryHuman gene therapy and imaging in neurological diseases.Efficient gene delivery and selective transduction of glial cells in the mammalian brain by AAV serotypes isolated from nonhuman primates.Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons.Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies.Optogenetic neuronal stimulation promotes functional recovery after strokeEfficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.Advances in gene therapy for movement disorders.Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death.Differential effects of two MRI contrast agents on the integrity and distribution of rAAV2 and rAAV5 in the rat striatum.Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis IImproved motor performance in Dyt1 ΔGAG heterozygous knock-in mice by cerebellar Purkinje-cell specific Dyt1 conditional knocking-outSystemic AAVrh10 provides higher transgene expression than AAV9 in the brain and the spinal cord of neonatal miceMethods for gene transfer to the central nervous system.The assessment of adeno-associated vectors as potential intrinsic treatments for brainstem axon regeneration.Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactionsA case for new therapy for diabetes, is it leptin?Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production.Gene therapy for misfolding protein diseases of the central nervous system.Long-term reversal of cholinergic neuronal decline in aged non-human primates by lentiviral NGF gene deliveryUnexpected off-targeting effects of anti-huntingtin ribozymes and siRNA in vivo.Insights into neurogenesis and aging: potential therapy for degenerative disease?Unique glycan signatures regulate adeno-associated virus tropism in the developing brain.Gene Manipulation Strategies to Identify Molecular Regulators of Axon Regeneration in the Central Nervous System.The generation of NGF-secreting primary rat monocytes: a comparison of different transfer methods.Parkin is protective for substantia nigra dopamine neurons in a tau gene transfer neurodegeneration model.Effects of AAV-mediated knockdown of nNOS and GPx-1 gene expression in rat hippocampus after traumatic brain injury.Herpes simplex virus type 1/adeno-associated virus hybrid vectors.Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice.
P2860
Q21129328-22ADB2A9-9BE6-4A53-97EF-4889F947D5D2Q26851517-E892A8F4-98A2-4E9B-82C6-AF0B766EA045Q31023442-C3B05950-A56A-497A-8318-5176C5AF5D63Q33713108-A28BAED9-26AA-4622-8F4E-B59365CE89F6Q33822237-BFDB61A6-4F13-464A-9EF3-DF48B45B7565Q33914222-694F8149-59BF-43C5-834A-D3839C430BEEQ34144724-01E19329-3EA3-4AEB-8512-A5DA80DA5C3DQ34330389-0AA88AAF-445C-49A5-A953-C89106A774A9Q34656049-E9CC4E4E-485C-4B4A-A727-E86CC72F484AQ34800137-A04045D6-D582-4079-80AE-7C9F6F71792EQ35194954-AF243062-5962-4551-BC04-8EB93FE6F43CQ35600310-DA365355-A3FE-40DD-A45A-9F42293DD2D4Q35878028-8D22BDF3-D449-44A7-A950-44F9AB2E6EEAQ35894587-2785BF8F-1E8A-41E6-B3D8-E1E2EBD848CFQ35902332-44540BDC-D029-4B1E-A067-B64F9BFED011Q36337994-280737AB-3D95-4623-B713-1B4A50413F01Q36498773-5004E7E5-D69E-4861-9D8C-6EF1B277D164Q36700857-27BC77AC-E9B4-45F1-B028-5F6FEE9F102CQ36960666-FFF31C93-FA8C-49FF-91A7-3114BBC7D5EEQ36983203-D7614B28-86F6-45CF-ABA0-604D2E20A6BAQ37076735-36A2D539-743A-4A18-8EAB-8E417B70B15EQ37226224-6BF786DA-AEC1-4DF6-A965-CD87AE961808Q37784147-C3184D17-A408-4E0D-A371-671054DA8346Q39795021-844C8055-4098-436F-9EF1-6CC726835A4FQ40077177-FABC6CBB-E83D-4B5B-B096-966407D53B0BQ40178328-40B452F8-F676-4BC4-97AB-673993CAB2ECQ40301036-30BD6BBC-0D1A-49AA-8C69-016FB83E6D3EQ41920871-EBB9EB2D-5E8A-4E66-A16E-F58FA8DD627DQ42448457-941BF03A-55B3-409D-94B3-E15A7242A955Q43100244-8A03AEE5-F408-46FA-8872-4E5BCA4B442B
P2860
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@ast
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@en
type
label
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@ast
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@en
prefLabel
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@ast
Clinical trials in neurological disorders using AAV vectors: promises and challenges.
@en
P1476
Clinical trials in neurological disorders using AAV vectors: promises and challenges
@en
P2093
Corinna Burger
Ronald J Mandel
P304
P577
2004-10-01T00:00:00Z